Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality.
about
Compartmentalization role of A-kinase anchoring proteins (AKAPs) in mediating protein kinase A (PKA) signaling and cardiomyocyte hypertrophyImpaired cardiac contractility response to hemodynamic stress in S100A1-deficient miceThe anti-apoptotic protein HAX-1 is a regulator of cardiac functionFibroblast-specific expression of AC6 enhances beta-adrenergic and prostacyclin signaling and blunts bleomycin-induced pulmonary fibrosis.Atrial chamber-specific expression of sarcolipin is regulated during development and hypertrophic remodeling.Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction.Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies.Autonomic control of blood pressure in mice: basic physiology and effects of genetic modification.Phospholamban overexpression in transgenic rabbitsPhospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transportThe emerging role of microRNAs in cardiac remodeling and heart failure.A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids.Effects of myostatin deletion in aging mice.The role of CaMKII regulation of phospholamban activity in heart disease.Factors controlling the activity of the SERCA2a pump in the normal and failing heart.Three basic residues of intracellular loop 3 of the beta-1 adrenergic receptor are required for golgin-160-dependent trafficking.Clinical applications of miRNAs in cardiac remodeling and heart failureRole of microRNAs in cardiac remodeling and heart failure.Rodent models of heart failure: an updated review.MiRNAs as potential molecular targets in heart failure.Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3.New and Emerging Therapies and Targets: Beta-3 Agonists.Ca2+ cycling and new therapeutic approaches for heart failure.Modeling Ca2+ dynamics of mouse cardiac cells points to a critical role of SERCA's affinity for Ca2+.Minimal force-frequency modulation of inotropy and relaxation of in situ murine heart.Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats.Calcium dynamics in the failing heart: restoration by beta-adrenergic receptor blockade.MicroRNA as a Therapeutic Target in Cardiac Remodeling.Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy.Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve.Dexamethasone-induced cardiac deterioration is associated with both calcium handling abnormalities and calcineurin signaling pathway activation.Regulator of G Protein Signaling 6 Protects the Heart from Ischemic Injury.
P2860
Q26995781-58CA8F61-7755-494B-A9EE-48C1D6CA49CFQ28209366-C9070AD0-09B9-4992-B303-0BCBE8819219Q28579303-BC785C10-DC4E-4B2F-99D0-FA2C2C111695Q33916995-8651009A-6135-4D09-9F35-49244F4AA3F1Q34184625-8CD0E64F-F755-4796-BBF7-4932E1694A24Q34321370-B3091205-E9A4-439B-8C9C-39BB7E0467B4Q34501994-3BC7D133-E326-4CC0-AC97-3FC98B49E303Q34637468-D64691FC-AA7E-459F-9D95-B3C636EF3DB4Q36628719-797EB672-300A-443A-A6A6-AFCBE6A7C95AQ37138913-55218078-8F85-4752-9CBE-45B9DBCD61E5Q37319218-8A02916D-D179-4C91-A331-13904C652212Q37357796-5A5A394B-651E-4CED-B55B-C8CBF14AEB9EQ37393064-F81B1E05-7CE1-4E91-A9B1-88D401AED2CDQ37555074-F81C46E2-4D06-41E5-B034-929F441636EAQ37630987-45DDF1DE-E0D2-4E1B-A562-7812C03322FFQ37645355-AAA3DF83-1C0F-458B-A42E-327532517950Q37852565-B848BC87-9A5A-4EA6-9AC5-EEE84E6B7D5FQ37856783-98E0B38E-9215-413D-ABB0-416D14A6142BQ37996857-6FD181A4-A0AF-4B3C-A4CC-64A57BCFE1EAQ38286294-36511718-DE88-4E4D-B5B7-57265E415A33Q38339372-CD1FA99D-92BD-40E4-A502-0096672CBD04Q39062830-9369FAFC-99A7-4A55-85DF-A81C436C1549Q39493909-6BCF74DD-3A23-4647-9F96-B893C4D91864Q42141286-96328146-538D-4607-ACD0-45CBF674D8B6Q42507340-81DBFA7F-7495-42E0-AF7C-07D8919BBCA3Q44138397-5B27C5BC-E21B-4CC3-9025-102B78DFDEC7Q44370057-8AB892A4-2B66-44C1-9FAA-DC733752A28AQ44732086-FB9282D5-A673-488C-B202-9B970513FC7DQ44970310-C464371F-378B-491A-B943-45F4CD609B68Q45185428-1AC79679-B5CA-4A50-9A7F-593EDAA16232Q48288742-A5B6F12E-19D4-47C3-B5E2-622772975E09Q48883868-707BA55C-305C-4E67-8AEE-9943426BAF26
P2860
Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Interactions between phosphola ...... omyopathy and early mortality.
@ast
Interactions between phosphola ...... omyopathy and early mortality.
@en
type
label
Interactions between phosphola ...... omyopathy and early mortality.
@ast
Interactions between phosphola ...... omyopathy and early mortality.
@en
prefLabel
Interactions between phosphola ...... omyopathy and early mortality.
@ast
Interactions between phosphola ...... omyopathy and early mortality.
@en
P2093
P356
P1433
P1476
Interactions between phosphola ...... omyopathy and early mortality.
@en
P2093
Abraham WT
Biniakiewicz D
Canning AM
Dorn GW 2nd
Kranias EG
Liggett SB
P304
P356
10.1161/01.CIR.103.6.889
P407
P577
2001-02-01T00:00:00Z